Compositions and methods for treating granulomatosis with polyangiitis
AssigneeCanem Holdings, LLC
InventorAdam Haeberle
Life of this patent
Estimating the term…
Abstract
The present specification disclose methods and uses for the treatment of a vasculitic syndrome. The disclosed methods comprise administering a composition comprising a Proteinase 3 (PR3) inhibitor to a patient in need thereof. Also disclosed are compositions comprising a PR3 inhibitor disclosed herein for use in the treatment of a vasculitic syndrome as well as use of a composition comprising a PR3 inhibitor disclosed herein in the treatment of a vasculitic syndrome. The present specification also discloses use of a composition comprising a PR3 inhibitor disclosed herein in the manufacture of a medicament for the treatment of a vasculitic syndrome.
Claims13
A method for treating Granulomatosis with Polyangiitis (GPA) in a patient in need thereof comprising administering a therapeutically effective amount of a Proteinase 3 (PR3) inhibitor to the patient, wherein administration inhibits a physiological function of PR3, thereby treating GPA, wherein the PR3 inhibitor is selected from elafin, Trappin-2, Eglin c, α-1 antichymotrypsin, and α-2 macroglobulin.
Dependencies are inferred from the claim text.